Registration
TODD STRATEGY GROUP for EXELIXIS, INC.
Firm
Client
Income
—
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Policy to advance pharmaceutical research and development. 340B. Implementation of Inflation Reduction Act of 2022.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL EDATTEL New | Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg |
| TAYLOR SEXTON New | Advisor to the Assistant Secretary for Preparedness & Response, HHS; Advisor to the Assistant Secretary of Legislation, HHS; Health Care Policy Fellow, Representative Michael Burgess |
| DANIEL M TODD New | Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid |
Medicare/Medicaid MMM
Policy to advance pharmaceutical research and development. 340B. Implementation of Inflation Reduction Act of 2022.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL EDATTEL New | Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg |
| TAYLOR SEXTON New | Advisor to the Assistant Secretary for Preparedness & Response, HHS; Advisor to the Assistant Secretary of Legislation, HHS; Health Care Policy Fellow, Representative Michael Burgess |
| DANIEL M TODD New | Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.